ArticleJournal of neuro-oncology2026
Can we make it up? - second-look surgery due to post-operative residual tumour in patients diagnosed with diffuse glioma.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeComplete resection (CR) of contrast-enhancing (CE) and non-contrast-enhancing (nCE) tumour compartments is a key prognostic factor in diffuse gliomas. However, despite an intraoperative impression of CR, early postoperative MRI may reveal residual tumour. This study evaluated outcomes of patients undergoing early second-look surgery for unplanned residual tumour volume.
methodsPatients undergoing surgery for diffuse gliomas between 2013 and 2023 were screened for surgical re-intervention within six weeks after initial resection. Patients undergoing early second-look surgery due to unplanned residual tumour on postoperative MRI were included. Volumetric MRI analyses, RANO resection classification, functional neurological outcomes, perioperative complications, and survival were assessed.
resultsAmong 1.558 glioma patients (CNS WHO grade 2–4), 447 underwent multiple surgeries, of whom 46 received second-look surgery for residual tumour. Resection status shifted from 80.4% submaximal after first surgery to supramaximal or maximal resection in 86.96% after second-look surgery. Residual tumour volumes were significantly reduced for both T1-CE and T2-nCE components (p < .001). Functional and neurological status remained stable (KPS and NIHSS, p > .5). In newly diagnosed glioblastoma patients (n = 28), RANO class 1 after second-look surgery was associated with longer overall survival compared to RANO 2B (13.8 vs. 8.0 months; p = .043). The 2- and 3-year OS rates were 33.34% and 16.67% in RANO class 1, while no patients in RANO class 2B survived beyond 2 years.
conclusionEarly second-look surgery for unplanned residual tumour enables a high rate of (supra-)maximal resections without compromising functional outcomes and may improve survival in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.